The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.

about

The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.

Item

http://www.wikidata.org/entity/Q46375923

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The Diagnostic, Prognostic, an ...... ldenstrom's Macroglobulinemia.

@en

The Diagnostic, Prognostic, an ...... ldenstrom's Macroglobulinemia.

@nl

type

Item

label

The Diagnostic, Prognostic, an ...... ldenstrom's Macroglobulinemia.

@en

The Diagnostic, Prognostic, an ...... ldenstrom's Macroglobulinemia.

@nl

prefLabel

The Diagnostic, Prognostic, an ...... ldenstrom's Macroglobulinemia.

@en

The Diagnostic, Prognostic, an ...... ldenstrom's Macroglobulinemia.

@nl

P1476

The Diagnostic, Prognostic, an ...... ldenstrom's Macroglobulinemia.

@en

P2093

Carolyn S Grove

http://www.w3.org/2001/XMLSchema#string

Chris Van Vliet

http://www.w3.org/2001/XMLSchema#string

Connull Leslie

http://www.w3.org/2001/XMLSchema#string

P2860

The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Oncogenically active MYD88 mutations in human lymphoma

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.

P31

scholarly article

case report

P356

10.3390/IJMS18102038

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chan Yoon Cheah

Collin K Chin

P577

2017-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28937595

http://www.w3.org/2001/XMLSchema#string

P932

5666720

http://www.w3.org/2001/XMLSchema#string